FDA Multi-Cycle Product Review Analysis To Begin In Fiscal 2004
Executive Summary
FDA expects an analysis of the "root causes" of multi-cycle product reviews to begin in fiscal year 2004, Office of New Drugs Director John Jenkins, MD, said June 24 during the Biotechnology Industry Organization annual meeting in Washington, D.C
You may also be interested in...
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Good Review Management Guidance To Be Tested By “Root Causes” Analysis
FDA will evaluate the impact of its Good Review Management Principles project through a prospective analysis of NME submissions, beginning with fiscal year 2005